Ipamorelin
Overview
Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue that selectively activates the ghrelin receptor (GHSR-1a). Its defining feature in the research literature is selectivity: it stimulates growth-hormone release with little effect on prolactin, cortisol or ACTH, and with minimal appetite stimulation — which distinguishes it from earlier GHRPs. It is a research compound.
Chemical Profile
| Property | Value |
|---|---|
| CAS number | 170851-70-4 |
| Class | Pentapeptide GHSR-1a agonist |
| Amino-acid sequence | H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂ |
| Molecular formula | C₃₈H₄₉N₉O₅ |
| Molecular weight | 711.86 g/mol |
| Purity (HPLC) | ≥ 98% |
| Appearance | White to off-white lyophilized powder |
- Class
- Pentapeptide GHSR-1a agonist
- Research status
- Preclinical and limited clinical
- Study route
- Subcutaneous
- Half-life
- ≈ 2 h
- Key feature
- Selective GH release, minimal prolactin/cortisol
Mechanism of Action
Ipamorelin binds GHSR-1a like the other GHRPs, but its selectivity profile is the point of interest: it drives GH release without meaningfully raising prolactin, cortisol or ACTH, and with little of ghrelin’s appetite effect. That “cleaner” signal is why it is often used as the reference selective secretagogue.
| Component | Detail |
|---|---|
| Primary target | GHSR-1a (ghrelin receptor) |
| G-protein coupling | Gαq/11 → PLC → IP₃/DAG → Ca²⁺ |
| GH release | Potent |
| Prolactin | Minimal |
| Cortisol / ACTH | No significant elevation |
| Appetite | Minimal (distinguishes it from ghrelin) |
Pharmacology
| Parameter | Value |
|---|---|
| Half-life (t½) | ≈ 2 h |
| Bioavailability (SC) | ≈ 80–90% |
| Time to peak (Tmax) | ≈ 15–30 min |
| Metabolism | Proteolytic degradation |
| Route of administration | Subcutaneous |
| Elimination | Renal (peptide fragments) |
Research Evidence
Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.
| Study type | Research focus | Reference |
|---|---|---|
| Rat pituitary cells | Potent, selective GH release | Raun K, et al. (1998/2005) |
| Ovariectomized rats | Bone-formation markers | GH-secretagogue bone literature |
| Healthy-volunteer study | GH response and selectivity | Ipamorelin clinical literature |
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
| Reported direction / finding | Context | Reference |
|---|---|---|
| Potent, selective GH release with minimal prolactin/cortisol | pituitary models | Raun K et al. |
| Bone-formation markers in ovariectomized models | rat bone | GH-secretagogue literature |
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
Dosing & Reconstitution Reference
Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.
| Parameter | Reference value |
|---|---|
| Research dose range (literature) | ≈ 200–500 µg per injection, in study protocols |
| Reconstitution solvent | Bacteriostatic water (0.9% benzyl alcohol) |
| Storage (lyophilized) | −20°C, protected from light |
| Storage (reconstituted) | 2–8°C, up to ~2–4 weeks |
| Do not use | If the solution is cloudy or contains particulates |
Safety Profile
Published research observations, provided for reference only. This material is not for human or veterinary use.
| Category | Published observations |
|---|---|
| Local tolerability | Mild injection-site reactions |
| Hormonal crosstalk | Minimal prolactin/cortisol elevation (its selling point) |
| Appetite | Minimal |
| Status | For research use only; not for human or veterinary application |
Physicochemical Properties
| Property | Value |
|---|---|
| Physical state | White to off-white lyophilized powder |
| Solubility (water) | Freely soluble |
| logP | ≈ −1.5 (hydrophilic) |
| pH (reconstituted) | 5.0–6.5 |
| Stability (lyophilized) | ≥ 24 months at −20°C |
Synthesis & Manufacturing
Ipamorelin is a C-terminally amidated pentapeptide made by Fmoc solid-phase synthesis. The non-standard residues — Aib and D-2-naphthylalanine — plus the two D-amino acids are what require dedicated building blocks.
| Step | Detail |
|---|---|
| Strategy | Fmoc solid-phase peptide synthesis |
| Resin | Rink amide resin (C-terminal amide) |
| Special residues | Aib, D-2-Nal, D-Phe |
| Coupling | HBTU / HOBt with DIPEA |
| Cleavage | TFA / TIPS / H₂O (95 : 2.5 : 2.5) |
| Purification | Preparative RP-HPLC (C18, TFA/ACN gradient) |
- Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
- Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
- Critical quality attributes: correct molecular weight and low deletion-peptide content. Confirm the D-residues and the α-aminoisobutyric acid (Aib).
Analytical Methods
| Method | Parameter | Typical result |
|---|---|---|
| RP-HPLC (C18, UV 214 nm) | Purity | ≥ 98% |
| HPLC retention | C18, reversed-phase TFA/ACN gradient | Single main peak |
| ESI-MS (positive mode) | Identity / mass | [M+H]⁺ ≈ 712 Da |
| MALDI-TOF | Mass confirmation | [M+H]⁺ ≈ 712 Da |
| Amino-acid analysis | Composition | Consistent with the stated sequence |
| LC-MS (extracted ion) | Deletion-peptide impurities | Within specification |
| Karl Fischer | Water content | < 6% |
| LAL assay | Endotoxin | Within specification |
| Ion chromatography | Residual TFA | < 500 ppm |
Representative RP-HPLC purity method:
- Column: C18, 5 µm, 250 × 4.6 mm
- Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
- Gradient: reversed-phase TFA/ACN gradient · Flow rate: 1.0 mL/min · Detection: UV 214 nm
- Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 712 Da). Confirm the D-residues and the α-aminoisobutyric acid (Aib).
Stability Data
Representative stability behaviour under common storage, handling and formulation conditions.
| Condition | Duration | Result |
|---|---|---|
| Lyophilized, −20°C, dark | ≥ 24 months | No significant degradation (purity > 97%) |
| Lyophilized, 2–8°C, dark | ≥ 12 months | Minimal degradation (purity > 95%) |
| Lyophilized, 25°C (accelerated) | 3 months | < 5% degradation |
| Reconstituted, 2–8°C, dark | 7–14 days | Minor degradation |
| Reconstituted, 25°C | 24–48 h | Use promptly |
| Light exposure (ICH Q1B) | 1.2 M lux·h | Generally light-stable |
| Freeze–thaw (−20°C ⇄ 25°C) | 3 cycles | Acceptable — aliquot to avoid repeats |
- Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
- Minimise freeze-thaw cycles; aliquot material used across many sessions.
- Key factor: Confirm the D-residues and the α-aminoisobutyric acid (Aib).
Selected References
- Raun K, et al. Ipamorelin, the first selective growth-hormone secretagogue. European Journal of Endocrinology.
- Growth-hormone-secretagogue and GHSR-1a pharmacology reviews.
Quality & Supply
- HPLC ≥ 98% purity with a Certificate of Analysis per batch
- Identity confirmed by LC-MS
- Research samples through to bulk, with worldwide delivery
- Custom quantities and packaging on request
Need Ipamorelin — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
